Andere talen Alterity Therapeutics Limited Nasdaq

Aandelen

ATHE

US02155X2053

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2 ^USD	-0,99%		-0,50%	-19,68%

08/05	Alterity Therapeutics Comité voor Gegevenscontrole Fase 2 beveelt voortzetting van klinische studie aan zoals gepland na derde evaluatie	CI
29/04	Alterity Therapeutics Limited presenteert nieuwe gegevens die het potentieel aantonen van ATH434 voor de behandeling van zeldzame neurodegeneratieve ziekten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	08/05
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	08/05
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	29/04
ADRs End Lower, Purple Biotech Ltd. Declines 29%	16/04
ADRs End Lower, Leju Holdings Ltd. Declines 72%	12/04
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	11/04
ADRs Close Lower; VIA Optronics AG Declines 30%	10/04
Top Midday Gainers	10/04
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	26/03
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	26/03
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	26/03
Genetic Technologies Appoints CFO	25/03
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	15/03
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	28/02
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	23/02
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	06/02
Alterity Therapeutics Completes Securities Purchase Plan	02/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alterity Therapeutics Limited Nasdaq

Aandelen

ATHE

US02155X2053

Andere talen

Filters